(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2025 (18.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/193584 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61P 9/12* (2006.01)
A61K 31/713 (2006.01) *A61P 13/12* (2006.01)

(21) International Application Number:
PCT/US2025/019127

(22) International Filing Date:
10 March 2025 (10.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/563,887 11 March 2024 (11.03.2024) US
63/749,238 24 January 2025 (24.01.2025) US

(71) Applicant: **REGULUS THERAPEUTICS INC.** [US/US]; 4224 Campus Point Court, Suite 210, San Diego, California 92121 (US).

(72) Inventors: **GARG, Rekha**; c/o Regulus Therapeutics Inc., 4224 Campus Point Court, Suite 210, San Diego, California 92121 (US). **KAMEL, Amin**; c/o Regulus Therapeutics Inc., 4224 Campus Point Court, Suite 210, San Diego, California 92121 (US). **LEE, Edmund Chun Yu**; c/o Regulus Therapeutics Inc., 4224 Campus Point Court, Suite 210, San Diego, California 92121 (US).

(74) Agent: **SCARR, Rebecca** et al.; McNeill PLLC, 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/193584 A1

(54) Title: COMPOUND FOR USE IN METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE

(57) Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.